|Study Description:||The goal of this clinical research study is to learn about the safety of giving |
Idelalisib (also known as CAL-101) in combination with rituximab, ofatumumab,
bendamustine, fludarabine, chlorambucil, everolimus, and bortezomib to patients
with NHL, MCL, or CLL. In another part of the study, participants will receive
Idelalisib with rituximab and lenalidomide. Researchers also want to learn if
this study drug combination can help to control the disease.